Completed PHASE3 INTERVENTIONAL 2-arm NCT02889302

An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

An Additional Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Sponsor: Kissei Pharmaceutical Co., Ltd.

Updated 8 times since 2017 Last updated: Dec 12, 2018 Started: Nov 15, 2016 Primary completion: Mar 31, 2018 Completion: Mar 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02889302, this PHASE3 trial focuses on Spinocerebellar Degeneration and remains completed. Sponsored by Kissei Pharmaceutical Co., Ltd., it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2019 — Jan 2021 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Dec 2018 — Jan 2019 [monthly]

Unknown Status PHASE3

Status: Active Not Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE3
Dec 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2017 — Dec 2017 [monthly]

Recruiting PHASE3

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kissei Pharmaceutical Co., Ltd.

Data source: Kissei Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Multiple Locations, Japan